(S)-N-[3-(3-Fluoro-4-iodo-phenyl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide → N-({(5S)-3-[3,5-difluoro-4-(2-oxopiperidin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide
Reaktionsgleichung
[F:1][C:2]1[CH:3]=[C:4]([N:10]2[CH2:14][C@H:13]([CH2:15][NH:16][C:17](=[O:19])[CH3:18])[O:12][C:11]2=[O:20])[CH:5]=[C:6]([F:9])[C:7]=1I.FC1C=C(N2[CH2:33][C@H:32]([CH2:34][NH:35][C:36](=[O:38])[CH3:37])OC2=O)C=CC=1I>>[F:1][C:2]1[CH:3]=[C:4]([N:10]2[CH2:14][C@H:13]([CH2:15][NH:16][C:17](=[O:19])[CH3:18])[O:12][C:11]2=[O:20])[CH:5]=[C:6]([F:9])[C:7]=1[CH:33]1[CH2:32][CH2:34][NH:35][C:36](=[O:38])[CH2:37]1Komponenten
3
Edukt 2
Produkt 1
Versuchsvorschrift
N-({(5S)-3-[3,5-difluoro-4-(2-oxopiperidin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide is prepared as in the route described in Example 16 substituting N-{[(5S)-3-(3,5-difluoro-4-iodophenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl}acetamide for 1 N-{[(5S)-3-(3-fluoro-4-iodophenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl}acetamide. 1H-NMR (CDCl3) δ: 7.13, 6.09, 5.8, 4.79, 4.01, 3.74, 3.68, 3.44, 2.75, 2.62, 2.31, 2.02, 1.94